Africa’s leading drug manufacturer Aspen Pharmacare Holdings has reportedly agreed to acquire a unit of competitor Mereck & Co in a deal worth about $1 billion. In a statement, Aspen CEO Stephen Saad said the acquisition will aid his company’s output in Latin America and Asia, where the firm looks to strength its roots. According to reports, the agreement involves the buyout of a products unit, which uses molecules for therapeutic treatment including hormone replacement therapy and oral contraceptives. Aspen’s drugs unit is based in the Netherlands. The deal is the largest divestment made by Mereck since 2009.
Featured News
Warren, Banks Call for FTC Investigation of Fire Truck Market Concentration
Jul 21, 2026 by
CPI
Metro Bank Weighs £2 Billion Bid for Aldermore
Jul 21, 2026 by
CPI
EU Antitrust Probe Deepens as Cemex Receives Formal Objections
Jul 21, 2026 by
CPI
Google Settles Russian Antitrust Case, Opens Android to Rival Search Services
Jul 21, 2026 by
CPI
Kentucky Settles Antitrust Claims Against Greystar in RealPage Rent-Setting Case
Jul 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes